First presentation of top-line efficacy and safety results from the Phase 4 DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) trial of adults with narcolepsy or idiopathic hypersomnia For U.S. media and investors only DUBLIN, Oct. 31, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eight abstracts presenting data from across its sleep portfolio were featured at the 37th annual Psych Congress, held in Boston from October 29 through November ...

DUBLIN, Oct. 23, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2024 third quarter financial results and provide a business and financial update.  Audio webcast/conference call: U.S. Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 9 ...

Shares of Jazz Pharmaceuticals (JAZZ) have gained 5.6% over the past four weeks to close the last trading session at $115.65, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $175.56 indicates a potential upside of 51.8%. The average comprises 18 short-term price targets ranging from a low of $113 to a high of $230, with a standard deviation of $33.87. While the lowest estimate i ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks. Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at ...

Investors interested in Medical - Drugs stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Zoetis (ZTS) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with speci ...

Shares of Jazz Pharmaceuticals (JAZZ) rose nearly 6% on Tuesday after it reported positive top-line results from the phase III IMforte study, which evaluated Zepzelca (lurbinectedin), combined with Roche's (RHHBY) Tecentriq (atezolizumab), in patients with extensive-stage small cell lung cancer (ES-SCLC). The Roche-sponsored IMforte study achieved statistically significant improvement in the primary endpoints of overall survival and progression-free survival. Treatment with the Zepzelca-Tecentriq combinatio ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for a free trial to Growth Stock Forum. Investors have shown little appreciation for two recent wins of Jazz Ph ...

Jazz Pharmaceuticals (JAZZ, Financial), a leading player in the narcolepsy market, is expanding its reach into other markets such as the non-small cell lung cancer (NSCLC) market by preparing a new biliary tract cancer drug; Zanidatamab. Zanidatamab that belongs to the NSCLC market is estimated to be worth $32 billion. Capturing even a modest 5% share could translate into $1.6 billion in additional revenue for Jazz. Considering the company's 2023 revenue of $3.8 billion, this represents a substantial growth ...

Jazz Pharmaceuticals (JAZZ) focuses on making drugs for neuroscience and oncology. The company derives most of its revenues from its sleep disorder drugs — Xywav and Xyrem. Xywav is a low-sodium formulation of Jazz's legacy drug, Xyrem. It also has a rapidly growing oncology portfolio. Jazz's revenues continue to benefit from strong demand for newer drugs like Xywav, Epidiolex and Rylaze. Jazz has also regularly boosted its commercial portfolio and pipeline through acquisitions. Jazz boasts a promising pipe ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true valuation met ...